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Abstract
Background: Adipocytes from mesenteric white adipose tissue amplify the inflammatory response and participate in
inflammation-driven immune dysfunction in Crohn’s disease by releasing proinflammatory mediators. Peroxisome
proliferator-activated receptors (PPAR)-a and -c, pregnane x receptor (PXR), farnesoid x receptor (FXR) and liver x-receptor
(LXR) are ligand-activated nuclear receptor that provide counter-regulatory signals to dysregulated immunity and
modulates adipose tissue.
Aims: To investigate the expression and function of nuclear receptors in intestinal and adipose tissues in a rodent model of
colitis and mesenteric fat from Crohn’s patients and to investigate their modulation by probiotics.
Methods: Colitis was induced by TNBS administration. Mice were administered vehicle or VSL#3, daily for 10 days.
Abdominal fat explants obtained at surgery from five Crohn’s disease patients and five patients with colon cancer were
cultured with VSL#3 medium.
Results: Probiotic administration attenuated development of signs and symptoms of colitis, reduced colonic expression of
TNFa, IL-6 and IFNc and reserved colonic downregulation of PPARc, PXR and FXR caused by TNBS. Mesenteric fat depots
isolated from TNBS-treated animals had increased expression of inflammatory mediators along with PPARc, FXR, leptin and
adiponectin. These changes were prevented by VSL#3. Creeping fat and mesenteric adipose tissue from Crohn’s patients
showed a differential expression of PPARc and FXR with both tissue expressing high levels of leptin. Exposure of these
tissues to VSL#3 medium abrogates leptin release.
Conclusions: Mesenteric adipose tissue from rodent colitis and Crohn’s disease is metabolically active and shows
inflammation-driven regulation of PPARc, FXR and leptin. Probiotics correct the inflammation-driven metabolic dysfunction.
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Introduction
Crohn’s disease is a chronic and progressive inflammatory
disorder of gastrointestinal tract. Transmural inflammation is the
histological hallmark of Crohn’s disease with inflammation
extending beyond the intestinal wall. An involvement of
mesenteric adipose tissue (MAT) is increasingly thought to provide
a mechanistic contribution to disease progression. This contention
is supported by the fact that at the onset of disease, although
patients show a weight loss, [1] a specific hypertrophy of MAT is
frequently identified [1–3]. Fat wrapping extending from the
mesenteric attachment and partially covering the intestinal
circumference, is common in both the small and large intestine
and is also considered a hallmark of Crohn’s disease [1]. This
ectopic tissue is referred to as ‘‘creeping fat’’ and is encroached at
the antimesenteric surface of the bowel. Surgeons are familiar with
creeping fat and use it as an anatomical marker to delineate the
extent of active disease [4]. Adipose tissue is increasingly identified
as a major endocrine organ from which either metabolic and
inflammatory signals propagate systemically, potentially modulat-
ing clinical features of Crohn’s disease. In Crohn’s disease patients
creeping fat is infiltrated by activated macrophages and releases
high amount of TNF-a and leptin, a proinflammatory adipokine,
indicating that this tissue could play a mechanistic role in
maintaining local and systemic inflammation [5,6]. In chronic
disorders such as diabetes and obesity MAT hypertrophy is
governed by the activation of a family of nuclear receptors-
peroxisome proliferator-activated receptor (PPAR) a and c,
farnesoid-x-receptor (FXR) and liver–x-receptor (LXR)- and
adipokynes that are well identified targets for medical interven-
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modulated by pharmacological interventions in Crohn’s disease
[7]. The commensal gut microbiota has profound effects on the
physiology of the host [8]. The intestinal microbiota may be
exerting effects beyond the intestine and patients with chronic
inflammatory disorders such as obesity and Type I diabetes display
an altered gut flora that may have a pathogenetic readout on the
phenotype of these disorders [8–10]. It is increasingly appreciated
that circulating levels of xeno- and endo-biotics including bile
acids, lipids and metabolism intermediates are regulated by gut
microbiota [11–13]. Nutrients and metabolites are transported
from the intestine to the liver via the afferent pathways, the i.e. the
portal vein and the lymphatic system exerting a wide range of
regulatory functions in abdominal tissues beyond the intestinal
wall. Decoding the interactions between metabolic intermediates
and endogenous receptors has lead to understanding that some of
these metabolites act as ligands or activators for nuclear receptors,
a large family of ligand activated regulatory factors that exert their
homeostatic functions at the interface between nutrients metab-
olism and innate immunity. Thus, activation of PPAR-a and c,
FXR and LXR by lipid mediators, bile acids and oxysterols
modulates lipid/cholesterol metabolism but also provides counter-
regulatory signals for cells of innate immunity [14-18]. Probiotics
which deliver some of the beneficial immunomodulatory effects of
the commensal gut microbiota and induce immune homeostasis
have been proposed as a suitable treatment for mild to moderate
IBD. Probiotics intervention results in a site-specific reduction of
inflammatory pathways with an increased expression of mediators
involved in PPAR signalling, a pathway that is counter-regulatory
for NF-kB [19]. The beneficial effects of probiotics extend outside
the intestine and probiotics have been shown to exert a beneficial
effects in obesity, NASH and diabetes despite the mechanisms
mediating these effects have not been elucidated [20]. In this study
we have investigated whether intestinal inflammation modulates
the expression of nuclear receptors in the intestine and MAT in a
rodent model of colitis and whether this pattern could be regulated
by administration of probiotics. In addition, we have investigated
whether this findings might have a translational relevance by
examining the expression of nuclear receptors and adipokines in
explants of creeping fat and MAT from Crohn’s disease patients.
Finally, by culturing creeping fat and MAT explants from Crohn’s
disease patients with conditioned medium from probiotics cultures
we have provided evidence that probiotics modulate leptin release.
Results
Anti-Inflammatory effects of VSL#3 the TNBS model of
colitis
Colon inflammation that develops in mice administered TNBS
is thought to be a model of Th1-mediated disease with dense
infiltrations of lymphocytes/macrophages in the lamina propria and
thickening of the colon wall [18,21]. The TNBS colitis is therefore
characterized by typical sign and symptoms of colitis, including
weight loss, diarrhea, macroscopic inflammation and prototypical
histological and biochemical intestinal changes including increased
levels of myeloperoxidase (MPO) activity, a biochemical marker of
neutrophils infiltration. No changes in body weight were recorded
in mice administered ethanol alone and followed for 7 days after
TNBS administration (data not shown). In order to assess whether
VSL#3 would exert immune-modulatory activity, mice adminis-
tered TNBS were treated with VSL#3 (50610
9 colony-forming
units (cfu)/day) for 5 days before induction of colitis. VSL#3
pretreatment effectively attenuated colitis development as mea-
sured by assessing local and systemic signs of inflammation.
VSL#3 administration protected against the development of
wasting disease measured by the weight loss and the diarrhea score
(Figure 1A and 1B; n=8–10, #p,0.05 versus naive group;
*p,0.05 versus TNBS group) and reduced the macroscopic score
of colitis (Figure 1 C; #p,0.05 versus control group; *p,0.05
versus TNBS group); moreover, it attenuated colon neutrophils
infiltration, as measured by assessing the colonic activity of MPO
(Figure 1 D #p,0.05 versus naive group; *p,0.05 versus TNBS
group). Mortality was 10% per group and was related to TNBS
inoculation. Indeed, mice deaths occurred mostly on day 7, i.e.
one day after TNBS inoculation (data not shown). Figure 2 (panel
A,D and G) illustrates a representative image of histopathological
analysis of colons obtained from each treatment group. Compared
with colons of naı ¨ve mice, colons obtained from mice administered
with TNBS showed an extensive cellular infiltrate, submucosal
edema and large areas of epithelial erosions. These changes were
robustly attenuated by VSL#3 treatment. To gain insights on the
immune-phenotype of colon lamina propria mononuclear cells
(LPMC), the phenotype of LPMC cells isolated from animals
administered TNBS alone or in combination with VSL#3 was
compared to LPMC isolated from naı ¨ve mice. The immune-
phenotypic characterization of these cells by CD3, CD19, CD14
and NK1.1 antibodies reveled that, in comparison to TNBS
treated mice, VSL#3 co-administration caused a slight, thought
significant, reduction in the percentage of CD14+ and CD3 +cells
(see Figure S1). This effect associates with a robust attenuation of
colonic expression of inflammatory and immune mediators
including IL-6, TNFa, IL-1b and INFc caused by TNBS
(Figure 3 Panel 1A, B, C and D ; n=5; #p,0.05 versus naı ¨ve;
*p,0.05 versus TNBS), while failed to change the mRNA levels of
IL-10 and TGF-b (Figure 3 Panel 1 E and F).
A growing body of evidence supports the notion that a mutual
inhibition between pro-inflammatory mediators and nuclear
receptors does exist in inflammatory bowel diseases (IBDs).
[22,23]. Consistent with this view, we found that acute TNBS-
colitis causes a robust decrease in the expression of several nuclear
receptor including PPARc, PXR and FXR. These changes were
antagonized by VSL#3 cotreatment (Figure 3, Panel 2; n=5;
#p,0.05 versus naı ¨ve; *p,0.05 versus TNBS). These changes in
gene product expression are mirrored by changes at the protein
levels, as demonstrated by the analysis of the colonic expression of
FXR protein (see Figure S2).
Effects of VSL#3 administration on the mesenteric
adipose tissue in mouse colitis
TNBS administration resulted in robust inflammatory changes
in the abdominal fat. Histophatlogy analysis of abdominal fat
isolated from TNBS treated mice revealed extensive venular
congestion, neutrophil margination and diapedesis and perivascu-
lar accumulation of neutrophils in the adipose tissue indicating
that TNBS-induced inflammatory changes in the colonic mucosa
are reflected in the surrounding fat (Figure 2, panel B,E,H). The
mesenteric fat depots from the TNBS treated mice were
characterized by an increased levels of the proinflammatory
cytokines, including TNF-a, IL-6 and MCP-1 compared to naive
mice (Figure 4, panel 1 A, B and C respectively n=5; #p,0.05
versus naı ¨ve). In addition we observed an induction in the
expression of leptin and adiponectin mRNAs (Figure 4 D and E
respectively n=5; #p,0.05 versus naı ¨ve) in mesenteric fat of
colitic mice. These changes were abrogated by VSL#3 admin-
istration (Figure 4 and Figure 3; n=5; #p,0.05 versus naı ¨ve;
*p,0.05 versus TNBS).
In contrast to the colon, we found that in comparison with fat
tissue from naive mice, the expression of PPARc and FXR was
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PPARa were unchanged and PXR was downregulated (Figure 4,
Panel 2; n=5; #p,0.05 versus naı ¨ve). VSL#3 coadministration
restored the PPARc and FXR mRNA levels (Figure 4, Panel 2;
n=5; *p,0.05 versus TNBS) while reduced drastically the LXR
expression (Figure 4, Panel 2; n=5; #p,0.05; *p,0.05 versus
TNBS). The expression of PXR was upregulated (Figure 4, Panel
2; n=5; #p,0.05 versus naı ¨ve; *p,0.05 versus TNBS).
Finally, we have investigated whether VSL#3 treatment could
attenuate signs and symptoms of an established colitis. For this
purpose animals were administered with VSL#3 (50
9 cfu/day)
starting one day after TNBS inoculation. As illustrated in Figure
S3, this treatment attenuated colitis development as evaluated by
assessing body weight changes, the macroscopic damage score and
the MPO activity (n=8-10. #p,0.05 versus naı ¨ve; *p,0.05
versus TNBS).
Expression of nuclear receptors, adipokines in creeping
fat and MAT explants from Crohn’s disease patients
Histopathological examination of mesenteric fat explants form
Crohn’s disease patient demonstrate a large number of inflam-
matory cells in creeping adipose tissue (Figure 5 A). In contrast,
very few inflammatory cells were detected in distal mesenteric
adipose tissue (Figure 5 B). Consistent with these changes creeping
fat explants were characterised by increased mRNA levels of the
proinflammatory cytokines such as TNFa, IL-6, MCP-1 and leptin
and adiponectin (Figure 6, panel 1 B, C, D and E respectively
n=5;*p,0.05). However, MAT explants obtained from Crohn’s
disease patients had a significant higher level of expression of
inflammatory mediators (IL-6, MCP-1) and leptin and adiponectin
when compared to MAT obtained from patients with colon
carcinomas (Figure 6, panel 1; n=5; # p,0.05). The creeping fat
was also characterized by a decreased expression of PPAR a and c
and FXR compared to MAT from Crohn’s disease patients and
control subjects (Figure 6, panel 2).
To determine whether VSL#3’s bacteria secrete factors
possessing anti-inflammatory activity, creeping fat and MAT
explants from Crohn’s disease were cultured with increasing
concentrations of VSL#3 CM for 48h. A shown in Figure 7,
explants from creeping fat released significant higher levels of
leptin, IL-6 and TNFa compared to MAT (#p,0.05; n=25).
Interestingly, treatment with VSL#3-CM (all doses) reduced
drastically the leptin production by creeping adipose tissue
(Figure 7 B; *p,0.05; n=25). In addition VSL#3-CM reduced
Figure 1. Anti-inflammatory activity of VSL#3 in TNBS colitis. Preteatment with VSL#3 (50610
9 colony-forming units (cfu)/kg/day) protects
against the development of TNBS-induced colitis in mice. Colitis was induced by intrarectal instillation of 1.5 mg of TNBS per mouse. Mice were
sacrificed 5 days after TNBS administration. (A and B) The severity of TNBS-induced inflammation (weight loss and fecal score) is reduced by VSL#3
administration. Data represent the mean 6 SE of 8–10 mice per group. (#p,0.05 versus naı ¨ve; *p,0.05 versus TNBS). (C and D) VSL#3 reduces local
signs of inflammation and inhibits the increase of macroscopic-score and neutrophil infiltration (MPO activity) induced by TNBS. Data represent the
mean 6 SE of 8–10 mice per group. (#p,0.05 versus naı ¨ve; *p,0.05 versus TNBS).
doi:10.1371/journal.pone.0022978.g001
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n=25).
Discussion
Probiotics which deliver some of the beneficial immunomodu-
latory effects of the commensal gut microbiota and induce
immune homeostasis are an effective treatment for mild to
moderate IBD [24–29]. Here we report that VSL#3 administra-
tion is effective in preventing development of an acute colitis
induced by TNBS and found that protection correlates with a
robust attenuation of inflammation as measured by assessing the
colitis macroscopic score, neutrophil infiltration and the mRNA
levels of TNFa, IL-1b, IL-6 and IFNc.
Nuclear receptors are a superfamily of regulatory factors that
exert homeostatic functions in the intestine at the interface
between nutrients metabolism and immunity. Activation of
PPARa ´ and a ˜, PXR, FXR and LXR by lipid mediators, bile
acids and oxysterols modulates lipid/cholesterol metabolism,
provides counter-regulatory signals for macrophages and protec-
tion in rodent models of dysregulated innate immunity [18,30]. A
confirmation of the inverse correlation existing between nuclear
receptors expression/activity and host susceptibility to inflamma-
tion in the intestinal compartment, comes from the observation
that acute exposure to TNBS results in a downregulation of
colonic expression of PPARa ˜, PXR, and FXR. Of relevance,
VSL#3 counter-reacts the effect of TNBS on inflammation and
preserves the intestinal expression of these nuclear receptors.
The adipose tissue is an important source of hormones and
cytokines [31]. Patients with Crohn’s disease accumulate adipo-
kine-releasing intra-abdominal fat from the onset of the disease
[32,33] indicating that expansion of mesenteric fat depots may be
an important source of inflammatory mediators in IBDs [34].
Here we have shown that acute colitis induced by TNBS in mice
associates with inflammatory changes in the mesenteric fat depots
sampled proximally to the inflamed intestine. These changes are
characterised by infiltration of mesenteric fat by leucocytes and
increased expression of TNFa, IL–6, MCP-1, that have a
mechanistic relevance in the development of systemic manifesta-
tions of IBDs [35].
The key finding of the present study, however, is that this
inflammation-driven metabolic activation of adipose tissue is
mediated by a differential regulation in the expression and several
nuclear receptors. An abnormal expression of PPARc, a nuclear
receptor which is predominantly expressed in adipocytes and
involved in adipogenesis, has been reported in the MAT of
Crohn’s patients [32]. Activation of PPARc has important
functionl consequences. Indeed PPARc is a potent inducer of
adipocytes growth and differentiation promoting their transition
from small, quiescent, adipocytes to large, activated, adipocytes
[36–38]. The fact that TNBS induced acute inflammation exerts
different effects on PPARc, with a reduced expression in the colon
and an increased expression in the mesenteric fact, seems to
support a role for this nuclear receptor in promoting the
acquisition of a pro-inflammatory phenotype by mesenteric
adipocytes. A similar pattern of expression was observed with
FXR. Indeed, while colitis associates with a reduced expression of
FXR in the colon, the expression of this nuclear receptor was
robustly increased in the mesenteric fat of TNBS-treated mice. We
and other have shown that FXR is involved in adipocytes
differentiation, adipogenesis, and lipid storage in vivo and in vitro
increasing the adiponectin through a mechanism that is partially
mediated by PPARc [39–40].
Figure 2. Histological analysis of colon and mesenteric adipose tissue of mice treated with TNBS alone or in combination with
VSL#3. (A, D and G) Histopathology analysis of colon samples, original magnification 106; H&E staining. (A) naı ¨ve mice; (D) TNBS administration
causes colon wall thickening and massive inflammatory infiltration in the lamina propria and mucosal erosions; (G) VSL#3 attenuates colon
thickening and inflammatory infiltration of the mucosa and submucosa. (B,C,E,F,H and I) Histologic analysis of mesenteric adipose tissue, H&E
staining. (B and C) Naı ¨ve mice, original magnification 106and 206;( E and F) TNBS group mice, original magnification 106and 206;( H and I)
VSL#3 treated mice, original magnification 106and 20x.
doi:10.1371/journal.pone.0022978.g002
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we have observed that in comparison to MAT obtained from
control subjects and Crohn’s patients, creeping fat tissue obtained
from Crohn’s disease patients is characterized by an increased
expression of IL-6, MCP-1 and leptin but has a reduced
expression of PPARa, PPARc and FXR. In contrast, in
comparison to MAT from control subjects, MAT tissue from
Crohn’s patients was characterised by an increased expression of
IL-6, MCP-1, leptin and adiponectin, as well as an increased
expression of PPARc and FXR. These changes seem to support a
different biological roles of creeping fat and MAT in Crohn’s
disease. However, it is noteworthy that even MAT was
characterized by the expression of a subset of genes known to
support an active adipocytes differentiation, i.e.PPARc and FXR
[39,40,41]. In aggregate these data seems to suggest that activation
of mesenteric adipose tissue is common in Crohn’s patients and
might contribute to development of local and systemic signs of
disease.
IBDs, including Crohn’s disease, are characterized by an
increase in mucosal permeability allowing luminal molecules to
travel through the intestinal wall or from lymphatic vessel to
surrounding tissues. Thus we have investigated whether probiotics
release factors that might drive the inflammatory response in the
adipose tissue. Interestingly we found that, while creeping fat
releases higher levels of leptin, IL-6 and TNFa compared to the
MAT explants obtained from Crohn’s disease patients, incubation
with VSL#3-CM conter-regulates the production of these
inflammatory mediators and abrogates the generation of leptin.
Leptin is an adipocyte-secreted hormone that regulates the size of
adipose tissue mass [42], reduces food intake and increases the
metabolic rate [42]. Despite the correlation between body mass
index and plasma leptin is usually preserved in IBDs [43], the
mechanistic role of hyperleptinaemia in the onset of anorexia and
weight loss associated with IBDs remains unclear [44]. However, it
well recognized that circulating levels of leptin does not accurately
reflect the local production of this hormone. Indeed a lack of
correlation between leptin mRNA levels and plasma levels in IBDs
has already been reported [45], reinforcing the notion that leptin
produced by MAT might not contribute significantly to the plasma
level of the hormone, but rather contributes to a local paracrine
effect in the intestine and mesenteric fat. In fact, leptin increases
TNFa secretion [45] and promotes changes in the balance
between Th1 and Th2 cytokines increasing the generation of Th1
cytokines (IFN-c and IL-2) and repressing IL-4 [45]. It is also well
recognized, that in the other tissue, such as the liver, leptin
promotes the activation of locally resident fibroblasts and leptin
production associates with liver fibrosis [46]. Because activation of
intestinal fibroblasts by locally released mediators and enhanced
Figure 3. VSL#3 attenuates inflammatory changes in the colon and restores nuclear receptors expression in mice administered
TNBS. (Panel 1. A–F) RT-PCR analysis of the expression of inflammatory cytokines (IL-6, TNFa, IL-1b, and INFc) and anti-inflammatory cytokines (IL-
10 and TGF-b) in colons obtained 5 days after TNBS. Data represent the mean 6 SE of 5 mice per group. (#p,0.05 versus naı ¨ve; *p,0.05 versus
TNBS). (Panel 2 A–E) RT-PCR analysis of the expression of PPARa, PPARc, FXR, LXR, PXR and CAR in colons removed 5 days after administration of
TNBS alone or in combination with VSL#3. Data represent the mean 6 SE of 5 mice per group. (#p,0.05 versus naı ¨ve; *p,0.05 versus TNBS).
doi:10.1371/journal.pone.0022978.g003
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Crohn’s disease, is could be speculated that the uncheked leptin
production we documented by creping fat and MAT might
contribute to intestinal fibrosis in Crohn’s patients. The demon-
stration that VSL#3-CM attenuates leptin production from MAT
and creeping fat explants might have therefore a role in explaining
the clinical effects of this agent, and paves the way to develop
specific therapies.
The increasing awareness that mesenteric and creeping fat
might contribute to inflammation and perhaps, to fibrosis, in
Crohn’s disease and that activity of these tissues could be regulated
through a differential expression of nuclear receptors, raises the
possibility to target these tissues with selective ligands for these
transcription factors. Selective PPARc agonists exerts anti-
inflammatory effects while regulating major metabolic pathways
in the abdominal fat and have been demonstrated useful in
reducing intestinal inflammation in IBDs [47]. However, the use
of PPARc ligands associates with an increased risk of cardiovas-
cular ischemic events, at least in the case of rosiglitazone [48].
Present results and previous data demonstrate that FXR exerts an
anti-inflammatory activity in rodent models of colitis [18] while
promoting a less activated phenotype in the adipose tissue [39],
suggesting a potential therapeutic role for ligands of this nuclear
receptor in the treatment of inflammation-driven activation of
adipose tissue in Crohn’s disease. However, further investigations
are required to better define interactions between intestinal
inflammation and mesenteric fat activation and whether mesen-
teric fat could be targeted by nuclear receptor modulators.
In conclusion, we have shown that colonic inflammation
regulates the expression of several nuclear receptor in MAT in a
model of colitis and in Crohn’s disease patients. MAT activation
could contribute to inflammation-driven immune and metabolic
dysfunction in these patients by generating a subset of pro-
inflammatory mediators and modulating the expression of several
nuclear receptors. These effects are counter-regulated by changing
the composition of enteric flora with a probiotic.
Materials and Methods
Animals
CD1 mice, 8 weeks of age, were obtained from Harlan Nossan
(Udine, Italy). Mice were housed under controlled temperatures
(22uC) and photoperiods (12:12-hour light/dark cycle), allowed
unrestricted access to standard mouse chow and tap water and
Figure 4. VSL#3 attenuates inflammation-driven metabolic dysfunction in the mesenteric adipose tissue. (Panel 1 A-E) RT-PCR
analysis of expression of inflammatory cytokines (TNFa, IL-6, and MCP1) and adipokines (leptin and adiponectin) in mesenteric adipose tissues. Data
represent the mean 6 SE of 5 mice per group. (#p,0.05 versus naı ¨ve; *p,0.05 versus TNBS). (Panel 2 A-E) RT-PCR analysis of the expression of
PPARa, PPARc, LXR, PXR and FXR in mesenteric adipose tissues obtained 5 days after administration of TNBS alone or in combination with VSL#3.
Data represent the mean 6 SE of 5 mice per group. (#p,0.05 versus naı ¨ve; *p,0.05 versus TNBS).
doi:10.1371/journal.pone.0022978.g004
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inclusion in an experiment. Protocols were approved by the
University of Perugia Animal Care Committee according to the
Italian guideline for care and use of laboratory animals. The ID
for this project is #98/2010-B. The authorization was released to
Prof. Stefano Fiorucci, as a principal investigator, on May 19,
2010.
Reagents
Purified myeloperoxidase (MPO) and tri-methylbenzidine,
trinitro-benzene sulfonic acid (TNBS) were obtained from
Sigma-Aldrich (Milan, Italy). The probiotics compound VSL3,
consisting of 8 strains of bacteria (L. acidophilus MB 443, L.
delbrueckii subsp. bulgaricus MB 453, L. casei MB 451, L. plantarum
MB 452, B. longum Y10, B. infantis Y1, B. breve Y8, and S. salivarius
subsp. thermophilus MB 455), was obtained from VSL Pharmaceu-
ticals.
Experimental Procedures
Mice were lightly anesthetized by intraperitoneal injection of
100 ml of ketamine/xylazine solution [18,21] per 10 g body weight
and then administered intrarectally (i.r.) with the haptenating
agent TNBS (1.5 mg/mouse) dissolved in ethanol 50%, via a 3.5
French (F) catheter equipped with a 1-ml syringe. The catheter
was advanced into the rectum for 4 cm and then the haptenating
agent was administered in a total volume of 150 ml. To ensure
distribution of the agent within the entire colon and cecum, mice
were held in a vertical position for 30 seconds. An additional
control group was obtained by administering mice with ethanol
alone on day 6. Animals (n=5) were followed for body weight
changes for 7 days.
Treated animals received, orally, saline or probiotics, daily, at
dose of 50610
9 colony-forming units (cfu)/kg/day (1.25610
9/
mouse) (n=10–8 for each group), 5 days before induction of
colitis. Mice were sacrificed 5 days after TNBS administration.
The mice were monitored daily for weigh loss and fecal score.
Probitics were dissolved each day in physiologic solution and
administrated orally at the final volume of 200 mL/mouse. The
TNBS group mice received the vehicle alone every day. Five days
after TNBS administration, surviving mice were sacrificed, colons
and mesenteric adipose tissue were removed and immediately
snap-frozen in liquid nitrogen and stored at 280uC until use. The
macroscopic appearance was analyzed under a dissecting
microscope (6 5) and graded for macroscopic lesions on a scale
from 0 to 10 based on criteria reflecting inflammation, such as
hyperemia, thickening of the bowel, and the extent of ulceration.
Neutrophil infiltration in the colon was monitored by measuring
MPO activity using a spectrophotometric assay with tri-methyl-
benzidine (TMB) as a substrate. Activity is expressed as mU per
mg protein.
Patients
MAT and creeping fat explants were obtained from five patients
affected by Crohn’s disease (2 women; mean age 3668 years old).
All patients underwent right ileocolonic resection because of
symptomatic ileal stenosis with transmural inflammation. All
patients had a stenotic disease complicated buy by ileocolonic
abscesses in 3 patients and an intestinal fistula, 2 patients. All were
treated with antibiotic (ciprofloxacin and metronidazole) for before
surgery. Anti-TNFa therapy was the main therapy in two patients.
All had been treated with azathioprine in the weeks before the
surgery. Five subjects with carcinoma of the right colon (2 women ;
mean age 4768 years old) served as controls. None of these
control subjects was obese. In patients with colon carcinoma
mesenteric fat samples were obtained in front of normal intestine
at a sufficient minimal distance from tumour. Adipose tissue
samples were immediately frozen in liquid nitrogen and stored at
280uC for subsequent mRNA analysis or processed to tissue
culture biopsy. An informed written consent on the use of removed
Figure 5. Distinctive histologic features the creeping fat and mesenteric adipose tissue in Crohn’s disease patients. Rappresentative
haematoxylin-eosin (H&E) staining of mesenteric adipose tissue of Crohn’s patients. Creeping fat original magnification 106and 206, respectively (A)
adipose tissue distal to intestinal mucosa of Crohn’s disease patients, original magnification 206(Bars: 100 mm) and 406(Bars: 50 mm), respectively
(B). Paired samples from three patients are shown.
doi:10.1371/journal.pone.0022978.g005
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of an ethical committee was not requested because for small
exploratory studies, by internal hospital guidelines, only the
informed consent by the patient is requested.
VSL#3 conditioned media preparations and human
adipose tissue cultures
To prepare conditioned medium (CM), 10 mg of VSL#3
probiotics formula was reconstituted in 10 ml of serum/antibiotic-
free Dulbeccos Modified Eagle’s cell culture medium and was
grown overnight in medium at 37uC without shaking. The CM
was centrifuged at 4,100 rpm for 10 min to separate the bacteria,
and the resulting supernatant was filtered two times through a
0.22- mm membrane (Millipore) to remove any insoluble particles
and diluted with DMEM cell culture medium free of serum and
supplemented with to have a final concentration of 10 mg/ml
bovine serum albumin, 5 mg/ml ethanolamine, 0.1 ng/ml sodium
selenite, 100 U/mL penicillin and 100 mg/mL streptomycin,
50 mg/ml gentamicin and 55 mM ascorbic acid. The pH of the
buffer was adjusted to 7.4 and then filtered through a 0.22- mm
filter (100-50-30-10%). The fat tissue samples were surgically
removed and placed in Hanks’ Balanced Salt Solution, (HBSS)
supplemented with 100 U/mL penicillin and 100 mg/mL strep-
tomycin. Fat tissue lobules were prepared under sterile conditions
by microdissection. Vessels and adjacent soft tissue were carefully
removed. After preparation, the fat tissue samples were washed
four time with HBSS supplemented with 300 U/mL penicillin and
300 mg/mL streptomycin. At least 25 fat tissue specimens,
creeping and distal, were cultured from each patient and secretion
of Leptin, Adiponectin, IL-6 (Orgenium Laboratories) and TNFa
(SABioscence) was determined. Based on this procedure, a total
number of n=25 tissue samples was incubated from 5 CD
patients, alone or in combination VSL#3 CM (100-50-30-10%).
The tissue samples were incubated in 1 mL medium for 48 h at
37uC in a 95% O2 and 5% CO2 incubator. Supernatants were
collected and stored at220uC. The wet weight of fat tissue was
measured (60–80 mg) in order to express the cytokine secretion as
pg/mg fat per 48 h.
Histological Analysis
For histological examination, tissues were fixed in 10% buffered
formalin phosphate, embedded in paraffin, sectioned, and stained
with hematoxylin and eosin (H&E). Histology images were
captured by a digital camera (Digital Microscope Camera
Figure 6. Expression of inflammatory mediators, adipokines and selected nuclear receptors in mesenteric adipose tissues from
Crohn’s patients. RT-PC analysis of expression of inflammatory TNFa, IL-6, MCP1, leptin and adiponectin (Panel 1 A-E) and nuclear receptors
(PPARa, PPARc, LXR, PXR and FXR) (Panel 2 A-E) in mesenteric adipose tissue (MAT) obtained from control subjects (N=5) (colon carcinoma) and in
Crohn’s patients (creeping fat and distal MAT) (N=5). Data represent the mean 6 SE of 5 different subjects per group. (#p,0.05 versus MAT of
control subjects ; *p,0.05 versus distal MAT obtained from Crohn’s disease patients).
doi:10.1371/journal.pone.0022978.g006
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software (Delta Sistemi, Rome, Italy).
Real-Time PCR
Quantization of the expression level of selected genes was
performed by quantitative real-time PCR (qRT-PCR). Total RNA
were obtained from colon and adipose tissue pieces (100–50 mg)
and isolated with TRIzol reagent (Invitrogen, Milan, Italy),
incubated with DNase I and reverse-transcribed with Superscript
II (Invitrogen) according to manufacturer specifications. For real-
time PCR, 50–25 ng of template was used in a 25- ml reaction
containing a 0.3 mM concentration of each primer and 12.5 mlo f
2x SYBR Green PCR Master Mix (Bio-Rad Laboratories,
Hercules, CA). All reactions were performed in triplicate using
the following cycling conditions: 2 min at 95uC, followed by 50
cycles of 95uC for 10 s and 60uC for 30 s using an iCycler iQ
instrument (Bio-Rad Laboratories). The mean value of the
replicates for each sample was calculated and expressed as cycle
threshold (CT). The amount of gene expression was then
calculated as the difference (DCT) between the CT value of the
sample for the target gene and the mean CT value of that sample
for the endogenous control (GAPDH). Relative expression was
calculated as the difference (DDCT) between the DCT values of the
test and control samples for each target gene. The relative level of
expression was measured as 2
2DDCT. All PCR primers were
designed using the software PRIMER3-OUTPUT using published
sequence data obtained from the NCBI database.
Mouse and Human primers were as follows:
mGAPDH: CTGAGTATGTCGTGGAGTCTAC and GTT-
GGTGGTGCAGGATGCATTG;
mIL1b: TCACAGCAGCACATCAACAA and TGTCCTCA-
TCCTCGAAGGTC;
mIL-6: CCGGAGAGGAGACTTCACAG and TCCACGAT-
TTCCCAGAGAAC;
mIL-10: GCTGGACAACATACTGCTAACC and CTGGG-
GCATCACTTCTACCA;
mINFc: GCGTCATTGAATCACACCTG and GACCTGT-
GGGTTGTTGACTC;
mMCP-1: CCCAATGAGTAGGCTGGAGA and TCTGGA-
CCCATTCCTTCTTG;
mTNFa: ACGGCATGGATCTCAAAGAC and GTGGGT-
GAGGAGCACGTAGT;
mTGFb: TGGCTTCAGCTCCACAGAGA and TGGTTGT-
AGAGGGCAAGGAC;
mLeptin: TTCACACACGCAGTCGGTAT and TCATTGG-
CTATCTGCAGCAC;
mAdiponectin: ACAATGGCACACCAGGCCGT and CCC-
TTAGGACCAAGAAGACCTGCA;
mPPARa: CAGAGGTCCGATTCTTCCAC and GATCAG-
CATCCCGTCTTTGT;
mPPARc: GCCAGTTTCGATCCGTAGAA and AATCC-
TTGGCCCTCTGAGAT;
mLXR: GCAGGACCAGCTCCAAGTAG and GGCTCAC-
CAGCTTCATTAGC;
Figure 7. VSL#3 CM modulates the production of mesenteric adipose tissue factors. Release of adiponectin, leptin, IL-6 and TNFa by
adipose tissue explants. Release by proximal (creeping fat) and distal MAT explants from 5 Crhon’s patients is shown. Creeping fat and MAT explants
were cultured alone or in combination with different concentrations of VSL#3 CM for 48 h. (#p,0.05 basal production (Ctrl) creeping versus MAT;
n=25; * p,0.05 verus control group, n=25).
doi:10.1371/journal.pone.0022978.g007
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TCAATAGGCAGGTC;
mFXR: TGTGAGGGCTGCAAAGGTTT and ACATCCC-
CATCTCTCTGCAC.
hPPARa: ACGATTCGACTCAAGCTGGT and GTTGTG-
TGACATCCCGACAG;
hPPARg: GCTGGCCTCCTTGATGAATA and TTGGG-
CTCCATAAAGTCACC;
hPXR: AGCTGGAACCATGCTGACTT and CACATA-
CACGGCAGATTTGG;
hFXR: TACATGCGAAGAAAGTGTCAAGA and ACTGT-
CTTCATTCACGGTCTGAT;
hTNFa: AACCTCCTCTCTGCCATCAA and GGAAGAC-
CCCTCCCAGATAG;
hIL6: AGGAGACTTGCCTGGTGAAA and CAGGGGTG-
GTTATTGCATCT;
hMCP1: CCCCAGTCACCTGCTGTTAT and TCCTGA-
ACCCACTTCTGCTT;
HLXR: CGCACTACATCTGCCACAGT and TCAGGCG-
GATCTGTTCTTCT;
hLeptin: GGCTTTGGCCCTATCTTTTC and GCCAGT-
TCTGGTCCATCTT;
hAdiponectin: CCTGGTGAGAAGGGTGAGAA and GTAA-
AGCGAATGGGCATGTT.
Statistical analysis
All values are expressed as the mean 6 SE of n mice per group.
Comparisons of more than 2 groups were made with a one-way
analysis of variance with post hoc Tukey tests. Differences were
considered statistically significant if p was ,0.05.
Supporting Information
Figure S1 LPMC were isolated from freshly obtained
colonic specimens. After excision of all visible lymphoid
follicles, colons were digested with type IV collagenase (Sigma)
for 20 min in a shaking incubator at 37uC; this step was repeated
twice. The released cells were then layered on a 40%-100%
Percoll gradient (Pharmacia, Upsala, Sweden) and spun at
1,800 rpm to obtain the lymphocyte-enriched populations at the
40–100% interface. For flow cytometry analysis 0.8610
6 LPMC
obtained from naı ¨ve and TNBS (1.5 mg/mouse) treated mice (4
after colitis induction) alone or in combination with VSL#3
(506109 colony-forming units (cfu)/kg/day) for 5 days before
induction of colitis. Cells were stained (20 min at 4u), with specific
mAbs against CD3, CD14, CD19, and NK-1.1 (phycoerythrin
(PE) or fluorescein isothiocyanate (FITC)--conjugated) (BD
Biosciences). At the end of incubation, cells were washed two
times with phosphate buffered saline (PBS) buffer and resuspended
in PBS containing formaldehyde (4%) prior to flow cytometric
analysis (Epics XL-2; Beckman Coulter, USA).
(PPT)
Figure S2 Total lysates from colon were prepared by
E1A-buffer. Protein levels in tissue extract were quantified with
Bradford reagent. Proteins, 30 mgrams, (a pool of 5 different
animals, 6 mgrams each) were separated by polyacrylamide gel
electrophoresis, transferred to nitrocellulose membranes (Bio-Rad,
Hercules, CA) and than probed with primary anti-FXR antibody
(0.5 mg/ml) (Ab 28676, Abcam). The anti-immunoglobulin G
Rabbit (Bio-Rad) was used as a secondary antibody, and specific
protein bands were visualized by chemoluminescence using
Supersignal West Dura reagent (Pierce, Rockford, IL).
(PPT)
Figure S3 Colitis was induced in Balb/c by intrarectal
administration of TNBS (0.5 mg/mouse) in 50% etha-
nol. To assess whether administration of VSL#3 would protect
against development of colitis, TNBS-treated mice were random-
ized to receive vehicle or probiotics, daily, (the day after TNBS
administration) at dose of 50610
9 colony-forming units (cfu)
(n=10 for each group). The mice were monitored daily for weigh
loss and fecal score (A and B). The macroscopic appearance was
analyzed under a dissecting microscope (x 5) and graded for
macroscopic lesions on a scale from 0 to 10 based on criteria
reflecting inflammation, such as hyperemia, thickening of the
bowel, and the extent of ulceration (C). Neutrophil infiltration in
the colon was monitored by measuring MPO activity using a
spectrophotometric assay with tri-methylbenzidine (TMB) as a
substrate (D). Activity is expressed as mU per mg protein.*P value
,.05 was considered significant vs Naive group. #P value ,.05
was considered significant vs TNBS group. The ANOVA test was
used for statistical comparisons.
(PPT)
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